ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Evaxion Biotech AS

Evaxion Biotech AS (EVAX)

3.00
-0.06
(-1.96%)
Closed September 14 4:00PM
2.82
-0.18
(-6.00%)
After Hours: 7:59PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
3.00
Bid
2.73
Ask
3.25
Volume
19,605
2.80 Day's Range 3.175
0.00 52 Week Range 0.00
Market Cap
Previous Close
3.06
Open
3.11
Last Trade
75
@
2.78
Last Trade Time
Financial Volume
$ 59,305
VWAP
3.025
Average Volume (3m)
-
Shares Outstanding
5,580,000
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-
Revenue
507k
Net Profit
-152.41M

About Evaxion Biotech AS

Evaxion Biotech AS is an artificial intelligence immunology platform company. It uses proprietary AI technology, engineering expertise, and drug development know-how to simulate the human immune system and generate predictive models to identify and develop efficacious immunotherapies for patients in... Evaxion Biotech AS is an artificial intelligence immunology platform company. It uses proprietary AI technology, engineering expertise, and drug development know-how to simulate the human immune system and generate predictive models to identify and develop efficacious immunotherapies for patients in the global market. Its two lead product candidates are EVX-01 and EVX-02, for the treatment of various cancers. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Horsholm, Dnk
Founded
-
Evaxion Biotech AS is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker EVAX. The last closing price for Evaxion Biotech AS was $3.06. Over the last year, Evaxion Biotech AS shares have traded in a share price range of $ 0.00 to $ 0.00.

Evaxion Biotech AS currently has 5,580,000 shares outstanding. The market capitalization of Evaxion Biotech AS is $17.07 million.

EVAX Latest News

Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01

Topline data from a one-year interim analysis of the ongoing phase 2 trial show that 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate 15 out of the 16...

Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2

New pre-clinical data demonstrates that the novel EVX-B2 mRNA vaccine candidate triggers a targeted immune response The specific immune response leads to the elimination of the gonorrhea...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NOVVUNova Vision Acquisition Corporation
$ 41.00
(207.35%)
17.4k
NOVVNova Vision Acquisition Corporation
$ 37.0001
(200.08%)
202.75k
SMXSMX Security Matters Public Company
$ 5.85
(138.78%)
49.72M
OMICSingular Genomics Systems Inc
$ 12.38
(119.12%)
2.72M
TILInstill Bio Inc
$ 84.75
(82.41%)
3.76M
GSIWGarden Stage Ltd
$ 2.9693
(-75.66%)
4.24M
UPCUniverse Pharmaceuticals Inc
$ 0.55
(-67.07%)
30.45M
VMARVision Marine Technologies Inc
$ 0.77
(-48.67%)
34.54M
PRLDPrelude Therapeutics Inc
$ 2.775
(-42.55%)
2.49M
CNEYCN Energy Group Inc
$ 0.4335
(-37.17%)
5.06M
NVDANVIDIA Corporation
$ 119.10
(-0.03%)
238.43M
XXII22nd Century Group Inc
$ 0.3447
(28.00%)
183.73M
IMRXImmuneering Corporation
$ 2.02
(41.26%)
136.36M
SQQQProShares UltraPro Short QQQ
$ 8.17
(-1.33%)
127.78M
MULNMullen Automotive Inc
$ 0.1328
(-20.48%)
120.81M

EVAX Discussion

View Posts
Monksdream Monksdream 2 months ago
EVAX under $3
👍️0
Monksdream Monksdream 2 months ago
EVAX under $3
👍️0
Monksdream Monksdream 2 months ago
EVAX under $5
👍️0
Monksdream Monksdream 4 months ago
EVAX under $5
👍️0
Monksdream Monksdream 6 months ago
EVAX new 52 week low
👍️0
Awl416 Awl416 7 months ago
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
👍️0
BooDog BooDog 7 months ago
Halted. Offering exercise @ $4???? no way, that'll get reoffered for lower imo.

https://www.globenewswire.com/news-release/2024/02/01/2822093/0/en/Evaxion-Biotech-Announces-Pricing-of-15-Million-Public-Offering.html
👍️0
da_stock_analyst da_stock_analyst 8 months ago
#EVAX 🔥 low float crazy stock! Can run big tomorrow! $evax
👍️0
subslover subslover 8 months ago
Thanks! 14.77 is INSANITY! Hey, look what is going on with AFIB. No news since November. I used to trade that one in the past and banked several times
👍️0
TheFinalCD TheFinalCD 8 months ago
nice trading, you got ,more than me

this POS hit 14.77 ah

got out at $12 and we make a nice living on buying and selling these POS Companies! :)))))
👍️0
Awl416 Awl416 8 months ago
LOL
👍️0
rdeano221 rdeano221 8 months ago
$EVAX Jan. 24, 2024, 07:32 AM
InvestorPlace - Stock Market News, Stock Advice & Trading Tips

Evaxion Biotech (NASDAQ:EVAX) stock is on the rise Wednesday after the company revealed a stake held by Merck (NYSE:MRK).

A filing with the Securities and Exchange Commission (SEC) notes that Merck now holds an 11.4% stake in Evaxion Biotech. That comes from the 2,297,884 shares of EVAX and warrants to acquire another 2,297,704 shares that the company owns.

The stake that Merck holds is based on the 40,204,700 shares outstanding as of Jan. 11, 2024. That comes from 37,906,996 shares of MRK stock outstanding and 2,297,704 shares issuable upon the exercise of warrants.
👍️0
subslover subslover 8 months ago
It's amazing what a couple of keywords can do! Excellent IR work. I got out at $12 and we make a nice living on buying and selling these POS Companies! :)))))
👍️0
TheFinalCD TheFinalCD 8 months ago
$13'S ON THAT NEWS, POST RS PLAYS CAN BE WILD

I BOUGHT AS LOW AS 7.77 BUY DIDNT HOLD


WHERE DID YOU SELL?

Message in reply to:
LOL. Looks fake but I'll take it, man! :)
👍️0
subslover subslover 8 months ago
$11.93 and halted again
👍️0
TheFinalCD TheFinalCD 8 months ago
OF COURSE 9.72 HALTED UP

OPEN $10+
👍️0
subslover subslover 8 months ago
Hey! its all about making $$$$ :)
👍️0
TheFinalCD TheFinalCD 8 months ago
9.50 WAS MY HIGHEST SELL

NOW 8.50
👍️0
TheFinalCD TheFinalCD 8 months ago
I SEE IT NOW... 1-10 RS

WHAT HAPPENED ON THE 22ND FOR EVAX TO DROP TO 3.36? -45%


Jan 23 2024 4.99 1.33 36.29% 5.55 5.57 4.15 1,225,974
Jan 22 2024 3.6612 -3.04 -45.36% 6.94 6.94 3.36 212,44
👍️0
TheFinalCD TheFinalCD 8 months ago
WHAT HAPPENED ON THE 22ND FOR NVAX TO DROP TO 3.36? -45%


Jan 23 2024 4.99 1.33 36.29% 5.55 5.57 4.15 1,225,974
Jan 22 2024 3.6612 -3.04 -45.36% 6.94 6.94 3.36 212,44
👍️0
TheFinalCD TheFinalCD 8 months ago
;LOOKS LIKE $10+ COMING SOON
👍️0
subslover subslover 8 months ago
Yeah, but well-written fluff. Took a position last night,not gonna hold it long
👍️0
TheFinalCD TheFinalCD 8 months ago
EVAX 8.88 you mean fluff?
👍️0
subslover subslover 8 months ago
LOL. Looks fake but I'll take it, man! :)
👍️0
subslover subslover 8 months ago
LOL. Looks fake but I'll take it, man! :)
👍️0
TheFinalCD TheFinalCD 8 months ago
EVAX 7.77 Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
https://www.globenewswire.com/news-release/2024/01/24/2815320/0/en/Evaxion-to-Develop-Tailored-Novel-Cancer-Vaccines-Based-upon-a-New-Untapped-Source-of-AI-Discovered-Targets.html

https://finviz.com/quote.ashx?t=EVAX&p=d#google_vignette
👍️0
Awl416 Awl416 8 months ago
LOL

Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
👍️0
subslover subslover 8 months ago
NEWS
Evaxion Announces Completion of ADS Ratio Change
COPENHAGEN, Denmark, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that the Company’s previously disclosed change to its ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS Ratio”), has been made effective. The ratio has changed from one (1) ADS representing one (1) ordinary share to a new ADS Ratio of one (1) ADS representing ten (10) ordinary shares (the “ADS Ratio Change”). The ADS Ratio Change became effective on January 22, 2024 (the “Effective Date”).

For the Company's ADS holders, the change in the ADS Ratio has the same effect as a one-for-ten reverse ADS split and is intended to further support the liquidity in the Company’s ADSs and to enable the Company to regain compliance with the Nasdaq minimum bid price requirement. The exchange of one (1) new ADS for every ten (10) then-held (existing) ADSs occurred automatically on the Effective Date, with the then-held ADSs being cancelled and new ADSs being issued by The Bank of New York Mellon, the depositary bank (the “Depositary”). Registered holders of the Company’s ADSs held in certificated form were required on a mandatory basis to surrender their certificated ADSs to the Depositary for cancellation and received one (1) new ADS in exchange for every ten (10) existing ADSs then-held. Holders of uncertificated ADSs in the Direct Registration System (DRS) and The Depository Trust Company (DTC) had their ADSs cancelled and automatically exchanged, receiving one (1) new ADS for every ten (10) existing ADS then-held. The Company’s ADSs continue to be traded on The Nasdaq Capital Market under the ticker symbol “EVAX”.

The ADS Ratio Change affects all shareholders uniformly and will not alter any shareholder’s percentage interest in the Company’s equity, except to the extent that the ratio change would have resulted in a shareholder owning fractional ADSs. No fractional new ADSs were issued in connection with the change in the ADS Ratio. Instead, fractional entitlements to new ADSs will be aggregated and sold by the Depositary, and the net cash proceeds from the sale of the fractional ADS entitlements (after deduction of fees, taxes and expenses) will be distributed to the applicable ADS holders by the Depositary.

As a result of the ADS Ratio Change, the ADS trading price is expected to increase proportionally, although the Company can give no assurance that the ADS trading price after the ADS Ratio Change will be proportionally equal to or greater than the previous ADS trading price prior to the change or that the Ratio Change will have any effect on the liquidity in the Company’s ADSs.
👍️0
Awl416 Awl416 8 months ago
Some would say unnecessary move AH

Of course they just did a RS too
👍️0
Disquisition Disquisition 8 months ago
INDESCRIBABLE DUMPING
👍️0
Renee Renee 8 months ago
EVAX: planned one for 10 reverse split for Jan. 22,2024:

https://hedgefollow.com/upcoming-stock-splits.php
👍️0
BooDog BooDog 9 months ago
Today's range $0.57 - $0.77
👍️0
BooDog BooDog 10 months ago
Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept

Proof of Concept – Evaxion’s AI-Immunology™ platform demonstrates success in designing precision cancer vaccines in hematological cancers by targeting a novel class of antigens
Broad Applicability – The vaccine concept holds tremendous potential, offering broad applicability and promising benefits for patients with hematological malignancies

COPENHAGEN, Denmark, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, proudly announces the presentation of its novel precision vaccine concept at the 65th American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, California, from December 9-12, 2023.

https://ih.advfn.com/stock-market/NASDAQ/evaxion-biotech-as-EVAX/stock-news/92667300/form-6-k-report-of-foreign-issuer-rules-13a-16
👍️0
BooDog BooDog 10 months ago
NEWS: Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01
October 31, 2023 11:15 ET
| Source: Evaxion Biotech


https://www.globenewswire.com/news-release/2023/10/31/2770437/0/en/Evaxion-Announces-Encouraging-Initial-Phase-2-Clinical-Data-on-Its-Personalized-Cancer-Vaccine-EVX-01.html
👍️0
BooDog BooDog 10 months ago
High $1.10.
👍️0
BooDog BooDog 11 months ago
Maybe this time the push actually happens!!
👍️0
BooDog BooDog 12 months ago
May be a push coming.

https://ih.advfn.com/stock-market/NASDAQ/evaxion-biotech-as-EVAX/stock-news/92119783/form-6-k-report-of-foreign-issuer-rules-13a-16
👍️0
BooDog BooDog 12 months ago
$EVAX $ WOULD BE EXCELLENT!
👍️0
BooDog BooDog 12 months ago
Probably end up on the OTC imo. They're bleeding themselves and must realize it by now. I'm not sure they can do a RS and maintain compliance without some serious funding. Which will likely be toxic.

just my guess. But, it can still be playable with the volatility.

All on thge ask @ .48...

0.48
132700
batx
0.48
132700
edgx
0.48
132700
NSDQ
0.48
132700
arcx

Crazy. Shorts are certainly taking advantage.

IMO
👍️0
Monksdream Monksdream 12 months ago
EVAX new 52 week low
👍️0
Monksdream Monksdream 12 months ago
Reverse split candidate or banishment to the OTC
👍️0
Monksdream Monksdream 12 months ago
Reverse split candidate or banishment to the OTC
👍️0
BooDog BooDog 12 months ago
Many of my markers are barely starting to push the oversolds. The float is still small enough anything is possible here.

Certainly getting raked over the coals.

Might take a block to roll the dice with soon.
👍️0
Monksdream Monksdream 12 months ago
EVAX new 52 week low
👍️0
Monksdream Monksdream 1 year ago
EVAX new 52 week low
👍️0
Monksdream Monksdream 1 year ago
EVAX new 52 week low
👍️0
BooDog BooDog 1 year ago
$EVAX Get'r done Kanstrup! BEFORE this gets the notice. Get back over the $.

strup.

Mr. Kanstrup brings 25 years of life science experience and comes with a very strong track record in leading strategy development as well as business development and with a broad understanding of capital markets and investor relations in listed and unlisted companies. Mr. Kanstrup has held several senior leadership positions at Novo Nordisk, including Head of Biopharma Operations. Mr. Kanstrup will succeed Dr. Norlén as the Company’s new CEO on September 1, 2023.

👍️0
AJ Freely AJ Freely 1 year ago
$EVAX- 👆 Up 8% Pre-Market/Current Price $1.17
👉Personalized Cancer Vaccine Biotech w/ Q4 '23 Catalyst-8/2
👉Announces financing commitments of $20m w/ Negma Group-8/1
👉Presents promising results on EVX-B1, an AI-designed vaccine for Staphylococcus aureus-7/31
👍️0
BooDog BooDog 1 year ago
10.88 price target. https://fintel.io/sfo/us/evax?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

I was looking for the $, we'll see which hits first!

EVAX[/url][tag]EVAX daily
👍️0
BooDog BooDog 1 year ago
They wasted no time issuing their milestone warrants. I'm thinking shorts took advantage as well. PM dip into the 1.30's, which I was able to take a nice partial (that remains to be seen if it turns out to be nice) right at 1.40.

Short term dip because of the warrants, I see this bouncing pretty good sooner or later.
👍️0

Your Recent History

Delayed Upgrade Clock